Observe Medical ASA (STU:OM50) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Observe Medical ASA EBITDA Margin % Related Terms
Observe Medical ASA EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Observe Medical ASA's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:OM50 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Observe Medical ASA's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Observe Medical ASA EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Observe Medical ASA's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Observe Medical ASA's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Observe Medical ASA (STU:OM50) has a EBITDA Margin % of -294.94% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Observe Medical ASA and its competitors. According to the industry distribution chart, Observe Medical ASA ranks #706 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 86.4%.
Is Observe Medical ASA's EBITDA Margin % too high?
Observe Medical ASA's current EBITDA Margin % is -294.94%. Based on the distribution chart, Observe Medical ASA ranks #706 out of 817 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Observe Medical ASA has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Observe Medical ASA's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Observe Medical ASA ranks #706 out of 817 companies for EBITDA Margin %. This places Observe Medical ASA in the lower half of its industry. The industry median EBITDA Margin % is 7.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.44, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Observe Medical ASA and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Observe Medical ASA's current EBITDA Margin % is -294.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Observe Medical ASA stock overvalued right now?
Observe Medical ASA (STU:OM50) has a current EBITDA Margin % of -294.94%. The stock's GF Value™ is €0.02, compared to a current price of €0.09 — trading 355% above its estimated fair value. The current EBITDA Margin % is -294.94%. Observe Medical ASA's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Observe Medical ASA (STU:OM50), the current EBITDA Margin % is -294.94% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Observe Medical ASA (STU:OM50) Overvalued in 2026?
Based on GuruFocus' analysis, Observe Medical ASA stock appears to be overvalued.
The current stock price of €0.09 is trading 355% above its estimated GF Value™ of €0.02.
Key valuation signals for STU:OM50:
EBITDA Margin %: -294.94%
GF Value™: €0.02 vs. price of €0.09 (355% above fair value)
No single metric tells the full story. See the STU:OM50 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Observe Medical ASA is a Nordic medtech company focused on the development, commercialization, and scaling of medical technologies for the healthcare markets. The company's portfolio of proprietary products consists of: Sippi, a CE marked digitalized system for urine output measurement, the UnoMeter portfolio consisting of manual urine output measurement products and solutions for measuring intra-abdominal pressure. The company operates internationally through subsidiaries in Norway, Sweden and Denmark.
30GF Score
Get the complete analysis for STU:OM50
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:OM50 has been successfully added to your 
